Compare SAFT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAFT | CMPX |
|---|---|---|
| Founded | 1979 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 927.5M |
| IPO Year | 2002 | 2020 |
| Metric | SAFT | CMPX |
|---|---|---|
| Price | $73.10 | $5.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.43 |
| AVG Volume (30 Days) | 69.5K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | ★ 40.17 | N/A |
| EPS | ★ 6.70 | N/A |
| Revenue | ★ $1,263,732,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $677.91 |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $67.04 | $1.40 |
| 52 Week High | $84.20 | $6.88 |
| Indicator | SAFT | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 46.25 | 49.44 |
| Support Level | $70.94 | $4.86 |
| Resistance Level | $74.12 | $5.77 |
| Average True Range (ATR) | 1.50 | 0.29 |
| MACD | 0.18 | 0.04 |
| Stochastic Oscillator | 55.05 | 72.50 |
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. The company operates in the business segment of Property and casualty insurance operations.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.